Rigel to Present at the Jefferies London Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial officer, will present a company overview at the Jefferies London Healthcare Conference on Tuesday, November 19, at 9:30 am GMT (4:30 am EST).

To access the live webcast or archived recording, visit the Investor Relations section of the company's website at www.rigel.com. Please connect to Rigel's website prior to the start of the live webcast to allow for any software downloads.

About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, the Company's marketed products and pipeline of potential products, visit www.rigel.com.

Contact for Investors & Media:
Investors: 
Rigel Pharmaceuticals, Inc. 
650.624.1232 
[email protected]

Media:
David Rosen 
Argot Partners 
646.461.6387
[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-to-present-at-the-jefferies-london-healthcare-conference-302302060.html

SOURCE Rigel Pharmaceuticals, Inc.